Andrea Denicoff

Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Ethan Basch, Bryce B. Reeve, Sandra A. Mitchell et al. · JNCI Journal of the National Cancer Institute · 2014 · 1.1K citations · Full text

Pharmacy, Oncology, Cancer Control +15

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 1K citations · Full text

Pharmacy, Oncology, Outcomes Research +13

Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement

Edward S. Kim, Suanna S. Bruinooge, Samantha Roberts et al. · Journal of Clinical Oncology · 2017 · 482 citations

Medicine, Child Health, Clinical Trial Regulation +16

Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Jennifer L. Hay, Thomas M. Atkinson, Bryce B. Reeve et al. · Quality of Life Research · 2013 · 168 citations · Full text

Medicine, Oncology, Outcomes Research +8

Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer.

Lalage M. Wakefield, John J. Letterio, T Chen et al. · PubMed · 1995 · 159 citations

Medicine, Endocrinology, Oncology +11